15 Amsterdam Rheumatology and Immunology Centre, Reade, Amsterdam, The Netherlands Objectives We sought to investigate whether genetic effects on response to TNF inhibitors (TNFi) in rheumatoid ...

Correspondence to Dr. Nunzio Bottini, Dept. of Medicine, University of California San Diego, MC0656, La Jolla, CA 92093, USA; nbottini{at}ucsd.edu; Professor Costantino Pitzalis, William Harvey ...

Background: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout. In Phase 1 healthy subject studies, ...

The goal of the Bone and Joint Decade is to improve the health related quality of life for people with musculoskeletal disorders throughout the world. Musculoskeletal disorders are the most common ...

Animal models of rheumatoid arthritis (RA) are widely used for testing potential new therapies for RA. However, the question of which animal model is most predictive of therapeutic efficacy in human ...

10 Division of Immunology and Rheumatology, Stanford University, Palo Alto, California, USA 11 Department of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA 12 ...

Correspondence to Dr Zachary Scott Wallace, Division of Rheumatology, Allergy, and Immunology and Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General ...

Objective Systemic sclerosis-associated pulmonary arterial hypertension differs from idiopathic pulmonary arterial hypertension with respect to histopathology, treatment responses and survival.

Department of Immunology and Transfusion Medicine, Ullevaal University Hospital, Oslo, Norway Correspondence to: Dr J Kjeldsen-Kragh, Department of Immunology and Transfusion Medicine, Ullevaal ...

Pathology Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Bruxelles, Belgium Correspondence to Professor F A Houssiau, Rheumatology Department, Cliniques ...

Objectives To identify factors that predict response to belimumab treatment in the phase 3 BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further analyse clinical ...

1 Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 2 University of Maryland, Baltimore, Maryland, USA Correspondence to Dr Michelle Petri, Professor of Medicine, Johns Hopkins ...